AI-designed bird flu vaccine protects every animal in lab tests

What's going on

A team from the University of Cambridge and its spinout DIOSynVax Ltd. has used artificial intelligence to design a bird flu vaccine meant to cover many variants at once. In animal tests with mice and ferrets, it protected every vaccinated animal against several variants circulating worldwide. The vaccine many governments have stockpiled in case of a human outbreak protected only about half in the same comparison. The study, titled "Broad Vaccine Protection Against Globally Diverse Influenza A H5Nx Viruses," was published in the journal Cell Reports Medicine. It was led by Professor Jonathan Heeney of the Laboratory of Viral Zoonotics in the Department of Veterinary Medicine. Zoonoses are diseases that jump from animals to humans.

According to the university, it's the third success for this AI-assisted development method. The vaccine isn't approved yet, and human trials are still to come.

How the AI designs the vaccine

The active ingredient in a vaccine is the antigen, a feature of the pathogen that shows the immune system what to fight. Conventional vaccines usually use the antigen from one specific, already known virus strain. When the virus mutates, the protection often no longer fits.

The Cambridge team took a different approach. It collected the genetic sequences of every bird flu virus that surveillance programs worldwide have recorded in wild animals, livestock and infected humans. A purpose-built AI tool processed this huge dataset and designed several "super-antigens" from it. These contain the features shared across the whole virus family, rather than the quirks of a single variant. The candidates were first tested in cell cultures, and the best one then went into animal testing.

"Rather than providing immunity against one bird flu variant, our new broad-spectrum vaccine protects against a huge range of variants. It's designed to anticipate the virus's evolution rather than react to it." – Jonathan Heeney

The team describes it as a "plug-and-play" approach. The idea is modular: the method stays the same and only the virus data gets swapped out. According to Heeney, the AI speeds up the design process enormously. The candidates are then tested in the lab for efficacy and safety.

The animal test results

Vaccinated mice and ferrets were infected with several genetically very different variants of the bird flu virus. All of these variants have already infected humans and are considered potential pandemic triggers. Ferrets are a standard model in flu research because influenza runs a similar course in them as in humans.

The stockpiled vaccine is based on representative virus samples from the World Health Organization's pandemic preparedness program. It was developed against one specific strain and, according to the study, offered little protection against other circulating strains. All figures come from animal tests and university announcements. Whether they carry over to humans has yet to be shown in clinical trials.

Why bird flu is so feared

Bird flu is currently spreading among animals worldwide and is considered a serious public health threat. Some human infections with North American variants have been mild. Variants in Southeast Asia, on the other hand, have caused severe illness with high death rates. Like the coronavirus, the bird flu virus is an RNA virus. Viruses like these mutate quickly, jump more easily from animals to humans, and evade the immune system and existing vaccines.

Migratory birds carry the virus in their gut over long distances and spread it through their droppings. This year it was detected in animals in Australia and New Zealand for the first time. Things get really worrying, Heeney says, when the virus adapts to the airways of mammals. Pigs have the same virus docking sites in their airways as humans. Bird flu that infects pigs could therefore become more contagious for humans too. Better vaccines for animals thus indirectly protect people as well.

One platform for many pathogens

Bird flu isn't the team's first project. Earlier this year, it reported that its broad-spectrum coronavirus vaccine had proven safe in human trials. It also published results showing its flu vaccine protects against human and swine flu viruses. According to a Pravda.ru report citing a study in the Journal of Virology, a computer-designed antigen protected pigs against a target flu strain and many other strains. It reduced viral shedding after H1N1 infection about as well as a conventional, strain-matched vaccine.

In the pipeline:

• a single vaccine against Lassa, Marburg and Ebola viruses: Ebola kills around half of those infected on average, and there's no approved vaccine or drug for Marburg.
• a seasonal flu vaccine designed to protect across several flu seasons. According to the team, preliminary results show that an antigen designed in 2018 still works seven years later.

The work is also getting a funding boost. According to Mirage News, the team, together with the universities of Regensburg and Southampton, received £4.28 million in October from UK research funder UKRI and the Department for Environment, Food and Rural Affairs (Defra). Pravda.ru reports £3.4 million for a three-year project with the Animal and Plant Health Agency (APHA) and DIOSynVax. It's part of a £54 million program with 18 projects. The sources don't make clear how these two figures relate. The UK government had previously invested £100 million in AI for biosecurity.

The bigger picture

The study is a tangible example of how AI can make a concrete difference in medicine. The AI doesn't replace lab work here; it shortens the search for a suitable antigen. The approach targets a fundamental problem in pandemic preparedness: governments currently stockpile vaccines against strains that are already known, so they're always one step behind the virus. Flu and COVID shots have to be updated every year for the same reason, which costs health systems a lot of money. A vaccine that covers many current, and possibly future, variants would be a real step forward.

There are several reasons for caution, though. The results come from experiments on mice and ferrets, and animal studies don't always translate to humans. The available reports don't say how many animals were tested or how long the protection lasts. Terms like "game changer" and "future-proof" come from the developers themselves. Heeney is also the founder of DIOSynVax and therefore has a financial stake in its success. Years of clinical testing likely lie ahead before there's an approved vaccine for humans.